BioNotebook: Aegerion, Questcor, Depomed 4Q updates; Neurocrine offering
This article was originally published in Scrip
Executive Summary
Aegerion falls on management commentary; Questcor foresees seasonal weakness; Depomed rises on sales gains, cash strategy; and Neurocrine prices $142m offering.